We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults".
- Authors
Boettcher, Michael; Becker, Corina
- Abstract
The study design was intended to mimic a potential use of sildenafil for the treatment of erectile dysfunction in patients with heart failure who were stable on the recommended vericiguat maintenance dose of 10 mg [[6]]. In line with the knowledge about the direct relationship between drug plasma levels and pharmacodynamic effects observed with sGC stimulators, combined treatment of vericiguat with single doses of sildenafil was generally well tolerated in healthy volunteers [[2]]. In addition, co-administration of vericiguat with sildenafil resulted in decreases in seated systolic blood pressure and diastolic blood pressure of less than or equal to 5.4 mmHg when compared with co-administration of placebo with sildenafil. Overall, the observed blood pressure effects with vericiguat and sildenafil in our study were lower than those observed with sildenafil alone, as the reported mean maximum decrease in supine systolic blood pressure following oral dosing of sildenafil 100 mg was 8.4 mmHg [[3]].
- Subjects
SILDENAFIL; NEPRILYSIN; IVABRADINE; ADULTS; PHARMACOKINETICS; PHARMACODYNAMICS; ANGIOTENSIN-receptor blockers; PHOSPHODIESTERASE inhibitors
- Publication
Clinical Pharmacokinetics, 2023, Vol 62, Issue 11, p1651
- ISSN
0312-5963
- Publication type
Article
- DOI
10.1007/s40262-023-01304-9